Clinical trials - Press Releases

Date	Title	Company
08-Nov-2022	Nouscom’s Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors	Nouscom
08-Nov-2022	Australia’s Telix Pharmaceuticals Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study	Telix Pharmaceuticals
08-Nov-2022	Peter MacCallum Cancer Centre and Cartherics Announce Collaboration to Develop Autologous CAR-T Cell Therapy for Cutaneous T-Cell Lymphoma	Cartherics
04-Nov-2022	Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers	Transgene
04-Nov-2022	Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjögren’s syndrome	Servier and OSE
03-Nov-2022	medmix Drug Delivery (Haselmeier™) and AARDEX® Group Join Forces to Improve Self-Administration of Injectable Drugs in Clinical Trials	AARDEX® Group
01-Nov-2022	CD Bioparticles Introduces Hydrophilic Coatings for Medical Applications	CD Bioparticles
01-Nov-2022	Amerigo Scientific Launches New Polyclonal Antibody to Human Blood Coagulation Factor XIII	Amerigo Scientific
28-Oct-2022	dMed \| Clinipace announce corporate name change to Caidya	ramarketing
27-Oct-2022	Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials	Boehringer Ingelheim
27-Oct-2022	Registration is now open for RNA Therapeutics Conference 2023	SAE Media Group
27-Oct-2022	Brain Implants Market worth US$ 13.3 Billion 2029 with a CAGR of 12.4 %	Prophecy Market Insights
27-Oct-2022	Prosthetics Market is estimated to be US$ 9.44 billion by 2030 with a CAGR of 4.5% during the forecast period 2030	Prophecy Market Insights
26-Oct-2022	CARMAT announces that it has received regulatory approvals to resume its clinical study in France	CARMAT
26-Oct-2022	New Analysis of UPLIZNA® (inebilizumab) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks	Horizon Therapeutics plc
21-Oct-2022	Speeding up trial enrolment can save billions	Panthera Biopartners
18-Oct-2022	1ST Biotherapeutics, Inc., Announces Positive Phase I Data of c-Abl Inhibitor in Neurodegeneration	1ST Biotherapeutics, Inc.
18-Oct-2022	AcuraBio Appoints Talented Senior Executives to Drive Global Growth Program	AcuraBio
17-Oct-2022	The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval	Novotech Health Holdings Pte Ltd
17-Oct-2022	XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer	XBiotech